WebJan 26, 2024 · Myovant Sciences, Inc. Third fiscal quarter 2024 total revenue of $100.2 million; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX® of $48.7 million... WebMar 31, 2024 · Purchase Agreement. In the first quarter of fiscal year 2024, Myovant further strengthened its balance sheet, raising $22.5 million with the completion under the ATM program. About Relugolix Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist that has been evaluated
Myovant Sciences Provides Recent Corporate Updates …
WebOct 24, 2024 · Fiscal year : FY2024: FY2024: FY2024: Consolidated net assets ($108) ($354) ($473) Consolidated total assets : $106: $725: $520: ... Myovant Sciences aspires to redefine care for women and men through purpose-driven science, empowering medicines, and transformative advocacy worldwide. Founded in 2016, Myovant has executed five … WebOct 19, 2024 · A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as … can heart attack symptoms linger
Myovant Sciences Announces Corporate Updates and Financial …
WebCommercial Achievements in Launch Year ~11,000 ~$57 Million 40% cumulative net revenues sequential volume patients treated generated growth in fiscal Q3 2024 1 2 3 ® ~1,800 258M unique treatment covered lives centers have prescribed across all channels 4 (1) Includes patients on free and commercial volumes. WebMar 31, 2024 · Fiscal year 2024 total revenue of $231.0 million , including net product revenues of $94.3 million ; fourth fiscal quarter 2024 total revenues of $57.6 million , … WebApr 11, 2024 · Myovant Sciences has a one year low of $7.67 and a one year high of $27.06. The company has a market capitalization of $2.62 billion, a PE ratio of -14.13 and a beta of 2.17. The company’s 50 ... can hear self in mic